Skip to main content
. 2021 Jan 20;49(1):0300060520982657. doi: 10.1177/0300060520982657

Figure 3.

Figure 3.

Comparison of the prevalence of absence of symptoms following treatment (T1) between different therapy groups in patients with (a) postprandial distress syndrome (group a); and (b) epigastric pain syndrome (group b). PPF, postprandial filling; ES, early satiety; EP, epigastric pain; EB, epigastric burning; AS, abdominal swelling; PPI, proton-pump inhibitor; PKT, prokinetics; ATC, antacids: *P ≤ 0.05; **P < 0.01; ***P < 0.001.